TFFP - TFF Pharma gains 5% on positive AUG-3387 in vitro data in COVID-19 Delta variant

Augmenta Bioworks and and TFF Pharmaceuticals (NASDAQ:TFFP) announce positive in vitro data indicating that their lead anti-COVID-19 monoclonal antibody (mAb) therapy, AUG-3387, binds to and neutralizes the SARS-CoV-2 Delta variant (B.1.617.2). TFFP shares up 4.7% premarket at $9.06. Both the companies plan to develop AUG-3387 as an inhaled therapy for the treatment of COVID-19 disease in two types of individuals: (1) those already infected with SARS-CoV-2 who are at a high risk for severe disease but not yet hospitalized, and (2) for the prevention of SARS-CoV-2 infection for individuals at high risk for severe disease. The companies have selected a final formulation of AUG-3387 that will be used to complete in vivo preclinical efficacy studies in the coming weeks and will proceed with toxicology studies by the end of 2021. Ongoing studies are expected to demonstrate that a sufficient dose of AUG-3387 to achieve a neutralizing concentration in the lungs can be delivered via already

For further details see:

TFF Pharma gains 5% on positive AUG-3387 in vitro data in COVID-19 Delta variant